Balighi Kamran, Heidari Sama, Kavyani Mohammadreza, Kamyab Hesari Kambiz, Tootoonchi Nasim
Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermopathology, Razi Hospital, Tehran University of Medical Science, Tehran, Iran.
Case Rep Dermatol. 2022 Nov 22;14(3):350-355. doi: 10.1159/000527913. eCollection 2022 Sep-Dec.
Bullous pemphigoid is the most common acquired bullous disease with an autoimmune basis and a tendency to involve mostly old people. By rising incidence of diabetes all over the world, consumption of antidiabetes medications has also increased. One of the most used antidiabetes drugs is gliptin family (dipeptidyl-peptidase 4 inhibitor). Recently, this class of oral antidiabetic agents showed a correlation with the occurrence of bullous pemphigoid and its subtypes, including mucous membrane pemphigoid and pemphigoid nodularis. We are reporting a case series of 4 diabetes patients that we diagnosed with bullous pemphigoid subtypes (mucous membrane pemphigoid, pemphigoid nodularis, and its rarest subtype, linear IgA bullous dermatosis) after taking different drugs of gliptin family.
大疱性类天疱疮是最常见的获得性自身免疫性大疱性疾病，多发于老年人。随着全球糖尿病发病率的上升，抗糖尿病药物的使用量也在增加。最常用的抗糖尿病药物之一是格列汀类（二肽基肽酶4抑制剂）。最近，这类口服抗糖尿病药物显示出与大疱性类天疱疮及其亚型（包括黏膜类天疱疮和结节性类天疱疮）的发生存在关联。我们报告了4例糖尿病患者的病例系列，这些患者在服用不同的格列汀类药物后被诊断为大疱性类天疱疮亚型（黏膜类天疱疮、结节性类天疱疮及其最罕见的亚型，线状IgA大疱性皮病）。
